Relationship between β-cell mass and diabetes onset

Regulation of blood glucose concentrations requires an adequate number of beta-cells that respond appropriately to blood glucose levels. beta-Cell mass cannot yet be measured in humans in vivo, necessitating autopsy studios, although both pre- and postmorbid changes may confound this approach. Autopsy Studies report deficits in beta-cell mass ranging from 0 to 65% in type 2 diabetes (T2DM), and similar to 70-100% in type 1 diabetes (T1DM), and. when evaluated, increased beta-cell apoptosis in both T1DM and T2DM. A deficit of beta-cell mass of similar to 50% in animal studies leads to impaired insulin secretion (when evaluated directly in the portal vein) and induction of insulin resistance. We postulate three phases for diabetes progression. Phase 1: selective beta-cell cytotoxicity (autoimmune in T1DM, unknown in T2DM) leading to impaired beta-cell function and gradual loss of beta-cell mass through apoptosis. Phase 2: decompensation of glucose control when the pattern of portal vein insulin secretion is sufficiently impaired to cause hepatic insulin resistance. Phase 3: adverse consequences of glucose toxicity accelerate beta-cell dysfunction and insulin resistance. The relative contribution of beta-cell loss versus beta-cell dysfunction to diabetes onset remains all area of controversy. However, because cytotoxicity Sufficient to induce beta-cell apoptosis predictably disturbs cell function it is naive to attempt to distinguish the relative contributions of these linked processes to diabetes onset.